ACCC | Observed Survival Benefit with Limited Exposure of Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer at a Large Community-Based Institution
Observed Survival Benefit with Limited Exposure of Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer at a Large Community-Based Institution
Upcoming Events
ACCC 43rd National Oncology Conference
In Person October 21, 2026 at 8:00 AM EDT450 Summer St, Boston, MA 02210, USAOmni Boston Hotel at the Seaport, Boston
In Person April 22, 2027 at 8:00 AM EDTInterContinental the Willard Washington D.C. by IHG, 1401 Pennsylvania Ave NW, Washington, DC 20004, USAWillard Intercontinental,